ChloroquineV1, Main, Exploration, bibRecord, 002F34

Formulation and pharmacokinetics of artemisinin and its derivatives

Identifieur interne : 002F34 ( Main/Exploration ); précédent : 002F33; suivant : 002F35

Formulation and pharmacokinetics of artemisinin and its derivatives

Auteurs : H. A. C. Titulaer [Pays-Bas] ; J. Zuidema [Pays-Bas] ; C. B. Lugt [Pays-Bas]

Source :

International Journal of Pharmaceutics [ 0378-5173 ] ; 1991.

RBID : ISTEX:176BED56FEA16E51E6F89E2DF1E3E401F5B8407A

English descriptors

Teeft :
- Absorption rate, Acta pharm, Antimalarial, Antimalarial action, Antimalarial activity, Aqueous suspension, Artemether, Artemisinin, Artemisinin curves, Artesunate, Available literature, Bioavailability, Blood cells, Clinical studies, Derivative, Dosing scheme, Drug absorption, Erythrocyte, Falciparum, Falciparum malaria, Hairless mice, High concentrations, High recrudescence rate, Highest concentrations, Intramuscular administration, Intramuscular injection, Kinetic aspects, Laboratory animals, Liquid chromatography, Malaria, More research, Oral administration, Oral dose, Parasite, Parasite clearances, Peak concentration, Peak concentrations, Pharmacokinetic, Pharmacokinetic parameters, Plasmodium, Plasmodium falciparum, Protein binding, Protein synthesis, Qinghaosu, Qinghaosu antimalaria, Recrudescence, Recrudescence rate, Rectal, Rectal administration, Research group, Rodent malaria, Sesquiterpene lactone, Shen, Shishan zhao, Sodium salt, Suppository, Titulaer, Trans, Warhurst, Zhao.

Abstract

Abstract: Artemisinin, the leading compound of a completely deviant class of drugs, might be of incredible importance in the combat of malaria. Although the herb from which it is isolated has been known for more than 2000 years, and over 2000 patients have been successfully treated in clinical studies, no pharmacokinetic data are available, and thus empirical formulations are used. In this review the available literature on formulation and kinetic aspects of artemisinin and its derivatives is reinterpreted and discussed in order to determine the kinetic requirements for a rational and optimal design of artemisinin formulations.

Url:

https://api.istex.fr/ark:/67375/6H6-675ZTQMF-4/fulltext.pdf

DOI: 10.1016/0378-5173(91)90213-8

Affiliations:

Pays-Bas

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001295
to stream Istex, to step Curation: 001295
to stream Istex, to step Checkpoint: 001D05
to stream Main, to step Merge: 003001
to stream Main, to step Curation: 002F34

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Formulation and pharmacokinetics of artemisinin and its derivatives</title>
<author><name sortKey="Titulaer, H A C" sort="Titulaer, H A C" uniqKey="Titulaer H" first="H. A. C." last="Titulaer">H. A. C. Titulaer</name>
</author>
<author><name sortKey="Zuidema, J" sort="Zuidema, J" uniqKey="Zuidema J" first="J." last="Zuidema">J. Zuidema</name>
</author>
<author><name sortKey="Lugt, C B" sort="Lugt, C B" uniqKey="Lugt C" first="C. B." last="Lugt">C. B. Lugt</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:176BED56FEA16E51E6F89E2DF1E3E401F5B8407A</idno>
<date when="1991" year="1991">1991</date>
<idno type="doi">10.1016/0378-5173(91)90213-8</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-675ZTQMF-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001295</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001295</idno>
<idno type="wicri:Area/Istex/Curation">001295</idno>
<idno type="wicri:Area/Istex/Checkpoint">001D05</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001D05</idno>
<idno type="wicri:doubleKey">0378-5173:1991:Titulaer H:formulation:and:pharmacokinetics</idno>
<idno type="wicri:Area/Main/Merge">003001</idno>
<idno type="wicri:Area/Main/Curation">002F34</idno>
<idno type="wicri:Area/Main/Exploration">002F34</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Formulation and pharmacokinetics of artemisinin and its derivatives</title>
<author><name sortKey="Titulaer, H A C" sort="Titulaer, H A C" uniqKey="Titulaer H" first="H. A. C." last="Titulaer">H. A. C. Titulaer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Pharmaceutics, Croesestraat 79</wicri:regionArea>
<wicri:noRegion>Croesestraat 79</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zuidema, J" sort="Zuidema, J" uniqKey="Zuidema J" first="J." last="Zuidema">J. Zuidema</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Pharmaceutics, Croesestraat 79</wicri:regionArea>
<wicri:noRegion>Croesestraat 79</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lugt, C B" sort="Lugt, C B" uniqKey="Lugt C" first="C. B." last="Lugt">C. B. Lugt</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>ACF-Chemie BV</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">International Journal of Pharmaceutics</title>
<title level="j" type="abbrev">IJP</title>
<idno type="ISSN">0378-5173</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1991">1991</date>
<biblScope unit="volume">69</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="83">83</biblScope>
<biblScope unit="page" to="92">92</biblScope>
</imprint>
<idno type="ISSN">0378-5173</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0378-5173</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Absorption rate</term>
<term>Acta pharm</term>
<term>Antimalarial</term>
<term>Antimalarial action</term>
<term>Antimalarial activity</term>
<term>Aqueous suspension</term>
<term>Artemether</term>
<term>Artemisinin</term>
<term>Artemisinin curves</term>
<term>Artesunate</term>
<term>Available literature</term>
<term>Bioavailability</term>
<term>Blood cells</term>
<term>Clinical studies</term>
<term>Derivative</term>
<term>Dosing scheme</term>
<term>Drug absorption</term>
<term>Erythrocyte</term>
<term>Falciparum</term>
<term>Falciparum malaria</term>
<term>Hairless mice</term>
<term>High concentrations</term>
<term>High recrudescence rate</term>
<term>Highest concentrations</term>
<term>Intramuscular administration</term>
<term>Intramuscular injection</term>
<term>Kinetic aspects</term>
<term>Laboratory animals</term>
<term>Liquid chromatography</term>
<term>Malaria</term>
<term>More research</term>
<term>Oral administration</term>
<term>Oral dose</term>
<term>Parasite</term>
<term>Parasite clearances</term>
<term>Peak concentration</term>
<term>Peak concentrations</term>
<term>Pharmacokinetic</term>
<term>Pharmacokinetic parameters</term>
<term>Plasmodium</term>
<term>Plasmodium falciparum</term>
<term>Protein binding</term>
<term>Protein synthesis</term>
<term>Qinghaosu</term>
<term>Qinghaosu antimalaria</term>
<term>Recrudescence</term>
<term>Recrudescence rate</term>
<term>Rectal</term>
<term>Rectal administration</term>
<term>Research group</term>
<term>Rodent malaria</term>
<term>Sesquiterpene lactone</term>
<term>Shen</term>
<term>Shishan zhao</term>
<term>Sodium salt</term>
<term>Suppository</term>
<term>Titulaer</term>
<term>Trans</term>
<term>Warhurst</term>
<term>Zhao</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Artemisinin, the leading compound of a completely deviant class of drugs, might be of incredible importance in the combat of malaria. Although the herb from which it is isolated has been known for more than 2000 years, and over 2000 patients have been successfully treated in clinical studies, no pharmacokinetic data are available, and thus empirical formulations are used. In this review the available literature on formulation and kinetic aspects of artemisinin and its derivatives is reinterpreted and discussed in order to determine the kinetic requirements for a rational and optimal design of artemisinin formulations.</div>
</front>
</TEI>
<affiliations><list><country><li>Pays-Bas</li>
</country>
</list>
<tree><country name="Pays-Bas"><noRegion><name sortKey="Titulaer, H A C" sort="Titulaer, H A C" uniqKey="Titulaer H" first="H. A. C." last="Titulaer">H. A. C. Titulaer</name>
</noRegion>
<name sortKey="Lugt, C B" sort="Lugt, C B" uniqKey="Lugt C" first="C. B." last="Lugt">C. B. Lugt</name>
<name sortKey="Zuidema, J" sort="Zuidema, J" uniqKey="Zuidema J" first="J." last="Zuidema">J. Zuidema</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F34 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F34 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:176BED56FEA16E51E6F89E2DF1E3E401F5B8407A
   |texte=   Formulation and pharmacokinetics of artemisinin and its derivatives
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Formulation and pharmacokinetics of artemisinin and its derivatives

Formulation and pharmacokinetics of artemisinin and its derivatives

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri